rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    SCNX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Scienture reports Q3 revenue of $1.22 million, up 256% sequentially
      Oct 22Investing.comSCNX
      Scienture Holdings Regains Nasdaq Compliance Amid Revenue Surge

      Detailed price information for Scienture Holdings Inc (SCNX-Q) from The Globe and Mail including charting and trades.

      Oct 20The Globe and MailSCNX
      Scienture reports Q3 revenue of $1.22M, up 256% sequentially
      Oct 13Investing.comSCNX
      SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth
      Oct 13Yahoo FinanceSCNX
      EXCLUSIVE: Scienture Revenue Soars 256% As Drugmaker Targets 2027 Profitability - Scienture Holdings (NAS

      Scienture Holdings reports Q3 revenue of $1.22M, up 256% QoQ, driven by Arbli growth and the launch of Rezenopy.

      Oct 13BenzingaSCNX
      EXCLUSIVE: Scienture Revenue Soars 256% As Drugmaker Targets 2027 Profitability
      Oct 13Yahoo FinanceSCNX
      Scienture’s Arbli added to three pediatric hospital formularies
      Oct 2Investing.comSCNX
      EXCLUSIVE: Scienture Expands Institutional Reach for Hypertension Drug with New Hospital Adoptions - Scie

      Three U.S. pediatric hospitals added Scienture's hypertension drug Arbli to their formularies, boosting institutional reach.

      Oct 2BenzingaSCNX
      EXCLUSIVE: Scienture Expands Institutional Reach for Hypertension Drug with New Hospital Adoptions

      Scienture Holdings Inc. (NASDAQ:SCNX) on Friday announced that three leading U.S. pediatric academic medical centers added its proprietary hypertension medication to their formularies. These specialized hospitals, which focus on treating children with severe and chronic medical conditions, now offer Arbli (losartan potassium) Oral Suspension, 10 mg/mL to their patients. “The opportunity is particularly compelling given Scienture’s high gross margins, providing significant operating leverage as w

      Oct 2Yahoo FinanceSCNX
      Scienture Holdings (SCNX) Stock Drops 19% After Hours: Here's What Happened - Scienture Holdings (NASDAQ:

      Scienture Holdings shares tumble 19% after hours following a newly announced 1-for-25 reverse stock split.

      Oct 1BenzingaSCNX
      Scienture Holdings to implement 1-for-25 reverse stock split
      Sep 30Investing.comSCNX
      Scienture secures distribution deal for naloxone nasal spray
      Sep 22Investing.comSCNX
      Scienture Holdings Updates Investor Presentation and Guidance

      Detailed price information for Scienture Holdings Inc (SCNX-Q) from The Globe and Mail including charting and trades.

      Sep 15The Globe and MailSCNX
      Scienture Holdings at H.C. Wainwright: growth through niche drugs
      Sep 14Investing.comSCNX

      This is the newest page. Registered accounts read further back.